Clinical update on cancer: molecular oncology of head and neck cancer

Y Suh; I Amelio; T Guerrero Urbano; M Tavassoli

doi:10.1038/cddis.2013.548

Clinical update on cancer: molecular oncology of head and neck cancer

Y Suh, I Amelio, T Guerrero Urbano, M Tavassoli

Centre for Host Microbiome Interactions

Research output: Contribution to journal › Article › peer-review

150 Citations (Scopus)

Abstract

Head and neck cancers encompass a heterogeneous group of tumours that, in general, are biologically aggressive in nature. These cancers remain difficult to treat and treatment can cause severe, long-term side effects. For patients who are not cured by surgery and/or (chemo)radiotherapy, there are few effective treatment options. Targeted therapies and predictive biomarkers are urgently needed in order to improve the management and minimise the treatment toxicity, and to allow selection of patients who are likely to benefit from both nonselective and targeted therapies. This clinical update aims to provide an insight into the current understanding of the molecular pathogenesis of the disease, and explores the novel therapies under development and in clinical trials.

Original language	English
Article number	e1018
Number of pages	12
Journal	Cell death & disease
Volume	5
DOIs	https://doi.org/10.1038/cddis.2013.548
Publication status	Published - Jan 2014

Keywords

Animals
Biological Markers
Head and Neck Neoplasms
Humans
Molecular Targeted Therapy
Signal Transduction

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/cddis.2013.548

Cite this

@article{8a12e91876ed4beca78ec8a1c832e0bd,

title = "Clinical update on cancer: molecular oncology of head and neck cancer",

abstract = "Head and neck cancers encompass a heterogeneous group of tumours that, in general, are biologically aggressive in nature. These cancers remain difficult to treat and treatment can cause severe, long-term side effects. For patients who are not cured by surgery and/or (chemo)radiotherapy, there are few effective treatment options. Targeted therapies and predictive biomarkers are urgently needed in order to improve the management and minimise the treatment toxicity, and to allow selection of patients who are likely to benefit from both nonselective and targeted therapies. This clinical update aims to provide an insight into the current understanding of the molecular pathogenesis of the disease, and explores the novel therapies under development and in clinical trials.",

keywords = "Animals, Biological Markers, Head and Neck Neoplasms, Humans, Molecular Targeted Therapy, Signal Transduction",

author = "Y Suh and I Amelio and {Guerrero Urbano}, T and M Tavassoli",

year = "2014",

month = jan,

doi = "10.1038/cddis.2013.548",

language = "English",

volume = "5",

journal = "Cell death & disease",

issn = "2041-4889",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Clinical update on cancer

T2 - molecular oncology of head and neck cancer

AU - Suh, Y

AU - Amelio, I

AU - Guerrero Urbano, T

AU - Tavassoli, M

PY - 2014/1

Y1 - 2014/1

N2 - Head and neck cancers encompass a heterogeneous group of tumours that, in general, are biologically aggressive in nature. These cancers remain difficult to treat and treatment can cause severe, long-term side effects. For patients who are not cured by surgery and/or (chemo)radiotherapy, there are few effective treatment options. Targeted therapies and predictive biomarkers are urgently needed in order to improve the management and minimise the treatment toxicity, and to allow selection of patients who are likely to benefit from both nonselective and targeted therapies. This clinical update aims to provide an insight into the current understanding of the molecular pathogenesis of the disease, and explores the novel therapies under development and in clinical trials.

AB - Head and neck cancers encompass a heterogeneous group of tumours that, in general, are biologically aggressive in nature. These cancers remain difficult to treat and treatment can cause severe, long-term side effects. For patients who are not cured by surgery and/or (chemo)radiotherapy, there are few effective treatment options. Targeted therapies and predictive biomarkers are urgently needed in order to improve the management and minimise the treatment toxicity, and to allow selection of patients who are likely to benefit from both nonselective and targeted therapies. This clinical update aims to provide an insight into the current understanding of the molecular pathogenesis of the disease, and explores the novel therapies under development and in clinical trials.

KW - Animals

KW - Biological Markers

KW - Head and Neck Neoplasms

KW - Humans

KW - Molecular Targeted Therapy

KW - Signal Transduction

U2 - 10.1038/cddis.2013.548

DO - 10.1038/cddis.2013.548

M3 - Article

C2 - 24457962

SN - 2041-4889

VL - 5

JO - Cell death & disease

JF - Cell death & disease

M1 - e1018

ER -

Clinical update on cancer: molecular oncology of head and neck cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this